Thyroid Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: THY128 MIFTS: 48	Thyroid Tumor Categories: Endocrine diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Thyroid Tumor

MalaCards integrated aliases for Thyroid Tumor:

Name: Thyroid Tumor ⁵⁸ ²⁸ ⁵

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare endocrine diseases

External Ids:

UMLS via Orphanet ⁷² C0040136

Orphanet ⁵⁸ ORPHA100087

Sources

Summaries for Thyroid Tumor

MalaCards based summary: Thyroid Tumor is related to follicular adenoma and thyroid carcinoma, familial medullary. An important gene associated with Thyroid Tumor is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and Disease. The drugs Hemostatics and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Thyroid Tumor

Diseases related to Thyroid Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)

#	Related Disease	Score	Top Affiliating Genes
1	follicular adenoma	30.1	RET PTEN HRAS BRAF
2	thyroid carcinoma, familial medullary	29.9	RET PRKAR1A KRAS BRAF
3	teratoma	29.8	PTEN KRAS AKT1
4	nodular goiter	29.6	RET HRAS BRAF
5	rectal benign neoplasm	29.5	PIK3CA KRAS HRAS
6	thyroid cancer, nonmedullary, 2	29.3	PTEN NRAS LRRC56 HRAS BRAF
7	adenoid cystic carcinoma	29.2	PTEN PIK3CA LRRC56 KRAS HRAS AKT1
8	adenoma	29.2	RET PRKAR1A PIK3CA KRAS HRAS BRAF
9	hashimoto thyroiditis	29.0	RET NRAS KRAS HRAS BRAF
10	differentiated thyroid carcinoma	28.9	RET NRAS KRAS HRAS BRAF
11	wilms tumor 1	28.8	PTEN KRAS HRAS BRAF AKT1
12	thyroid gland follicular carcinoma	28.8	RET PTEN PIK3CA NRAS HRAS BRAF
13	thyroid gland anaplastic carcinoma	28.4	RET PTEN PIK3CA NRAS HRAS BRAF
14	cowden syndrome	28.3	RET PTEN PRKAR1A PIK3CA KRAS HRAS
15	adenocarcinoma	28.3	RET PTEN PIK3CA KRAS HRAS BRAF
16	neurofibromatosis	28.2	RET PTEN NRAS KRAS HRAS BRAF
17	thyroid gland cancer	28.0	RET PTEN PIK3CA NRAS LRRC56 KRAS
18	squamous cell carcinoma	28.0	PTEN PIK3CA NRAS KRAS HRAS BRAF
19	renal cell carcinoma, nonpapillary	27.6	RET PTEN PIK3CA NRAS KRAS HRAS
20	breast cancer	27.1	RET PTEN PIK3CA NRAS LRRC56 KRAS
21	thyroid gland medullary carcinoma	11.1
22	multiple endocrine neoplasia, type iia	11.0
23	thyroid carcinoma	10.7
24	thyroid cancer, nonmedullary, 1	10.5
25	goiter	10.4
26	papillary carcinoma	10.4
27	trachea carcinoma in situ	10.2	KRAS HRAS
28	common bile duct neoplasm	10.2	KRAS HRAS
29	ampulla of vater benign neoplasm	10.2	KRAS HRAS
30	bladder urachal carcinoma	10.2	KRAS HRAS
31	cutaneous-skeletal hypophosphatemia syndrome	10.2	LRRC56 HRAS
32	urachus cancer	10.2	KRAS HRAS
33	adenosquamous lung carcinoma	10.2	KRAS HRAS
34	descending colon cancer	10.2	KRAS HRAS
35	mucinous intrahepatic cholangiocarcinoma	10.2	KRAS HRAS
36	sigmoid neoplasm	10.2	KRAS HRAS
37	appendiceal neoplasm	10.2	KRAS HRAS
38	pancreatic mucinous cystadenoma	10.2	KRAS HRAS
39	transverse colon cancer	10.2	KRAS HRAS
40	noonan syndrome-like disorder with loose anagen hair 1	10.2	KRAS HRAS
41	liver angiosarcoma	10.2	KRAS HRAS
42	ascending colon cancer	10.2	KRAS HRAS
43	mucinous lung adenocarcinoma	10.2	KRAS HRAS
44	cystadenofibroma	10.2	KRAS HRAS
45	endosalpingiosis	10.2	KRAS HRAS
46	ovarian mucinous neoplasm	10.2	KRAS HRAS
47	appendix adenocarcinoma	10.2	KRAS HRAS
48	multiple mucosal neuroma	10.2	RET PTEN
49	skin lipoma	10.2	RET PTEN
50	large cell carcinoma with rhabdoid phenotype	10.2	KRAS HRAS

Graphical network of the top 20 diseases related to Thyroid Tumor:

Sources

Symptoms & Phenotypes for Thyroid Tumor

GenomeRNAi Phenotypes related to Thyroid Tumor according to GeneCards Suite gene sharing:

²⁵ (show all 41)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.99	HRAS BRAF PIK3CA KRAS
2	Decreased viability	GR00055-A-2	10.99	HRAS BRAF PIK3CA KRAS
3	Decreased viability	GR00055-A-3	10.99	KRAS
4	Decreased viability	GR00106-A-0	10.99	KRAS
5	Decreased viability	GR00221-A-1	10.99	AKT1 HRAS NRAS PRKAR1A PIK3CA RET
6	Decreased viability	GR00221-A-2	10.99	AKT1 HRAS PRKAR1A PIK3CA RET KRAS
7	Decreased viability	GR00221-A-3	10.99	AKT1 HRAS NRAS PRKAR1A
8	Decreased viability	GR00221-A-4	10.99	AKT1 PRKAR1A BRAF PIK3CA RET
9	Decreased viability	GR00249-S	10.99	AKT1 BRAF
10	Decreased viability	GR00301-A	10.99	BRAF RET KRAS
11	Decreased viability	GR00381-A-1	10.99	BRAF KRAS
12	Decreased viability	GR00402-S-2	10.99	PIK3CA RET
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.92	KRAS
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	9.92	PRKAR1A
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-130	9.92	RET
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.92	BRAF
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.92	PTEN
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	9.92	PTEN
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.92	PTEN
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	9.92	RET
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	9.92	HRAS
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-205	9.92	PRKAR1A
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.92	AKT1 RET
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.92	PTEN
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	9.92	KRAS
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-28	9.92	HRAS RET
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-3	9.92	NRAS
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.92	PTEN
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.92	BRAF
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.92	RET
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.92	AKT1 PIK3CA RET
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.92	KRAS PTEN
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-66	9.92	PTEN
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	9.92	AKT1
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-72	9.92	NRAS
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.92	RET
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	9.92	HRAS
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.92	AKT1 RET
39	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	9.92	HRAS PTEN
40	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	9.92	PTEN
41	Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation	GR00363-A	8.65	HRAS

MGI Mouse Phenotypes related to Thyroid Tumor:

⁴⁵ (show all 21)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.33	AKT1 BRAF HRAS KRAS LRRC56 NIBAN1
2	growth/size/body region	MP:0005378	10.31	AKT1 BRAF HRAS KRAS LRRC56 NIBAN1
3	neoplasm	MP:0002006	10.24	AKT1 BRAF HRAS KRAS NRAS PIK3CA
4	normal	MP:0002873	10.24	AKT1 BRAF HRAS KRAS NIBAN1 NRAS
5	cardiovascular system	MP:0005385	10.2	AKT1 BRAF HRAS KRAS LRRC56 NIBAN1
6	muscle	MP:0005369	10.18	AKT1 BRAF HRAS KRAS PIK3CA PRKAR1A
7	endocrine/exocrine gland	MP:0005379	10.18	AKT1 BRAF HRAS KRAS NRAS PIK3CA
8	digestive/alimentary	MP:0005381	10.15	BRAF HRAS KRAS NRAS PIK3CA PRKAR1A
9	immune system	MP:0005387	10.14	AKT1 BRAF KRAS LRRC56 NIBAN1 NRAS
10	cellular	MP:0005384	10.13	AKT1 BRAF KRAS NRAS PIK3CA PRKAR1A
11	embryo	MP:0005380	10.11	AKT1 BRAF KRAS NRAS PIK3CA PRKAR1A
12	behavior/neurological	MP:0005386	10.09	AKT1 BRAF HRAS KRAS NRAS PIK3CA
13	liver/biliary system	MP:0005370	10.04	AKT1 BRAF KRAS NRAS PRKAR1A PTEN
14	limbs/digits/tail	MP:0005371	10.03	BRAF KRAS NRAS PRKAR1A PTEN RET
15	respiratory system	MP:0005388	10.02	AKT1 BRAF HRAS KRAS LRRC56 PRKAR1A
16	pigmentation	MP:0001186	10	BRAF KRAS NRAS PRKAR1A PTEN
17	reproductive system	MP:0005389	9.97	AKT1 BRAF KRAS LRRC56 NIBAN1 PIK3CA
18	skeleton	MP:0005390	9.91	AKT1 BRAF HRAS KRAS NRAS PIK3CA
19	hematopoietic system	MP:0005397	9.81	AKT1 BRAF KRAS NIBAN1 NRAS PRKAR1A
20	mortality/aging	MP:0010768	9.7	AKT1 BRAF HRAS KRAS LRRC56 NRAS
21	integument	MP:0010771	9.32	AKT1 BRAF HRAS KRAS LRRC56 NIBAN1

Sources

Drugs & Therapeutics for Thyroid Tumor

Drugs for Thyroid Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hemostatics

Phase 3

Dexmedetomidine

Approved, Experimental, Vet_approved

86347-14-0, 113775-47-6

68602 5311068

Remifentanil

Approved

132875-61-7

60815

Desflurane

Approved

57041-67-5

42113

Iodine

Approved, Investigational

7553-56-2

807

Cadexomer iodine

Experimental

94820-09-4

Analgesics

Neurotransmitter Agents

Adrenergic alpha-Agonists

Adrenergic Agonists

Adrenergic Agents

Anesthetics, Inhalation

Anesthetics, General

Hypnotics and Sedatives

Analgesics, Opioid

Analgesics, Non-Narcotic

Narcotics

Anesthetics

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy	Unknown status	NCT01551914	Phase 3
2	Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry	Unknown status	NCT01668238
3	Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy	Unknown status	NCT01338597
4	Contrast-enhanced Ultrasound in Thyroid Tumor by Sonozoid	Completed	NCT04574258
5	Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules	Completed	NCT04594720
6	Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy	Completed	NCT02412150		Desflurane;Remifentanil;Dexmedetomidine;Normal saline
7	Prospective and Retrospective Thyroid Cancer Database	Recruiting	NCT04031638
8	Effect of Improved Endotracheal Intubation Procedure Combined With Early Oral Intake on Postoperative Recovery Quality of Patients Undergoing Intraoperative Recurrent Laryngeal Nerve Monitoring.	Not yet recruiting	NCT05624463
9	Effect of Early Postoperative Drinking Water on Postoperative Recovery Quality of Patients With Thyroid Surgery	Not yet recruiting	NCT05532384

Search NIH Clinical Center for Thyroid Tumor

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Interferon Alfa-2b

lenvatinib

levothyroxine

Levothyroxine Sodium

liothyronine

liothyronine sodium

sorafenib

Thyroglobulin

THYROID (BEEF)

thyroid (USP)

THYROID PWDR

thyrotropin alfa

Vandetanib

Sources

Genetic Tests for Thyroid Tumor

Genetic tests related to Thyroid Tumor:

#	Genetic test	Affiliating Genes
1	Thyroid Tumor ²⁸

Sources

Anatomical Context for Thyroid Tumor

Organs/tissues related to Thyroid Tumor:

MalaCards : Thyroid, Lymph Node, Breast, Thymus, Lung, Trachea, Endothelial

Sources

Publications for Thyroid Tumor

Articles related to Thyroid Tumor:

(show top 50) (show all 1660)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
3	Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors. ⁵	Isham CR...Bible KC	24628546	2014
4	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. ⁵	Ho AL...Fagin JA	23406027	2013
5	AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. ⁵	Couto JP...Soares P	23056499	2012
6	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. ⁵	Wells SA...Schlumberger MJ	22025146	2012
7	The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. ⁵	Verbeek HH...Hofstra RM	21470995	2011
8	Targeted therapies for thyroid tumors. ⁵	Sherman SI	21455200	2011
9	Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. ⁵	Carr LL...Martins RG	20847059	2010
10	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. ⁵	Lam ET...Shah MH	20368568	2010
11	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. ⁵	Wells SA...Schlumberger M	20065189	2010
12	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. ⁵	Hoftijzer H...Smit JW	19773371	2009
13	Phase II trial of sorafenib in metastatic thyroid cancer. ⁵	Kloos RT...Shah MH	19255327	2009
14	Phase II trial of sorafenib in advanced thyroid cancer. ⁵	Gupta-Abramson V...Brose MS	18541894	2008
15	Hyperactive Ras in developmental disorders and cancer. ⁵	Schubbert S...Bollag G	17384584	2007
16	Molecular biology of the MEN2 gene. ⁵	Santoro M...Vecchio G	9681850	1998
17	Thyroid tuberculosis diagnosed as papillary thyroid carcinoma with fever of unknown origin. ⁶²	Kinoshita I...Kawata R	34657776	2022
18	Intrathyroidal Thymic Carcinoma: A Retrospective Case Series Study. ⁶²	Liang J...Xu H	36408572	2022
19	Anesthetic management of trachea with huge thyroid tumor compression: A case report. ⁶²	Jin B...Zhang X	36456440	2022
20	A Case of Thyroid Carcinoma Showing Thymus-Like Differentiation With Breast Cancer Susceptibility Gene 2 Mutation: A Case Report and Literature Review. ⁶²	Kuroki M...Horikawa Y	36426335	2022
21	Case Report: Giant Thyroid Angiolipoma-Challenging Clinical Diagnosis and Novel Genetic Alterations. ⁶²	Wilkins R...Zhou F	36255668	2022
22	Downhill varices in the hypopharynx due to huge thyroid tumor: a case report. ⁶²	Nagaoka R...Sugitani I	36273906	2022
23	Using the Baidu index to understand Chinese interest in thyroid related diseases. ⁶²	Hu Q...Zhang F	36229549	2022
24	FBCU-Net: A fine-grained context modeling network using boundary semantic features for medical image segmentation. ⁶²	Yu M...Gao J	36240598	2022
25	Ferroptosis Inducers in Thyroid Cancer. ⁶²	Sekhar KR...Baregamian N	36195678	2022
26	A computed tomography-based radiomic nomogram for predicting lymph node metastasis in patients with early-stage papillary thyroid carcinoma. ⁶²	Lai L...Wei X	34859689	2022
27	[Risk factors for recurrence and survival analysis in locally advanced T4a papillary thyroid carcinoma after R0 resection]. ⁶²	Chen JM...Shen X	36177557	2022
28	Follicular Neoplasm of Thyroid Revisited: Current Differential Diagnosis and the Impact of Molecular Testing. ⁶²	Ohori NP...Nishino M	36102526	2022
29	Anaplastic thyroid tumor as an embolic source of metastasis. ⁶²	Gonzalez Rodriguez P...Palones FJG	35936021	2022
30	Thyroid metastasis revealing a lung adenocarcinoma: A case report and review of the literature. ⁶²	Elouarith I...Jahid A	36055168	2022
31	Subcutaneous axillary primary epithelioid hemangioendothelioma: report of a rare case. ⁶²	Niwa T...Seto Y	36083389	2022
32	ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis. ⁶²	Li W...Jiang G	36070054	2022
33	Survival-based bioinformatics analysis to identify hub long non-coding RNAs along with lncRNA-miRNA-mRNA network for potential diagnosis/prognosis of thyroid cancer. ⁶²	Morovat P...Samadani AA	36149574	2022
34	MiR-203a-3p, miR-204-3p, miR-222-3p as useful diagnostic and prognostic tool for thyroid neoplasia spectrum. ⁶²	Stojanovic S...Isic Dencic T	36103016	2022
35	Safety and Efficacy of Transoral Robotic Thyroidectomy for Thyroid Tumor: A Systematic Review and Meta-Analysis. ⁶²	Kang YJ...Hwang SH	36077768	2022
36	Assessment of Preoperative TSH Serum Level and Thyroid Cancer Occurrence in Patients with AUS/FLUS Thyroid Nodule Diagnosis. ⁶²	Kaliszewski K...Rudnicki J	36009464	2022
37	Retraction notice to "Transnasal humidified rapid-insufflation ventilatory exchange can be utilized in tracheal stenosis caused by thyroid tumor" [J. Clin. Anesth. 62(2020) 109727]. ⁶²	Ueshima H...Otake H	35396112	2022
38	Fumarate Hydratase is a Novel Gene for Familial Non-Medullary Thyroid Cancer. ⁶²	Alzahrani AS...Al-Hindi H	35751867	2022
39	Primary pulmonary epithelioid angiosarcoma with thyroid tumor history: A case report and literature review. ⁶²	Yu L...Qian X	35761817	2022
40	Nomograms based on preoperative multimodal ultrasound of papillary thyroid carcinoma for predicting central lymph node metastasis. ⁶²	Dai Q...Leng X	35226156	2022
41	Hypofractionated radiation therapy of a thyroid tumor in a pet raccoon (Procyon lotor). ⁶²	Kroncke C...Gardhouse S	35784773	2022
42	Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity. ⁶²	Honold L...Hermann S	34750717	2022
43	Thyroid tumor ratio: Improving the assessment of the impact of size in pediatric thyroid cancer. ⁶²	Paik C...Austin J	35322489	2022
44	MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer. ⁶²	Hamidi AA...Moghbeli M	35659780	2022
45	Extracellular vesicles from thyroid cancer harbor a functional machinery involved in extracellular matrix remodeling. ⁶²	Bravo-Miana RDC...Donadio AC	35849996	2022
46	Nerve autofluorescence under near-ultraviolet light: cutting-edge technology for intra-operative neural tissue visualization in 17 patients. ⁶²	Dip F...Rosenthal RJ	34694489	2022
47	Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor. ⁶²	Ramirez-Moya J...Riesco-Eizaguirre G	35562181	2022
48	The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer. ⁶²	Achilla C...Chatzikyriakidou A	35489753	2022
49	Use of ultrasonographic shear wave measurements to diagnose thyroid metastasis from breast carcinoma. ⁶²	Hoshi M...Sugitani I	35644558	2022
50	Giant cervical goiter in Hashimoto's thyroiditis: A case report. ⁶²	Tao T...Jing-Dong L	35538703	2022

Sources

Genes for Thyroid Tumor

Genes related to Thyroid Tumor (4 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵	17384584 19255327 19773371 (more) 23406027 25157968 26619011
2	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵	17384584 19255327 19773371 (more) 23406027 24628546 25157968 26619011
3	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵	17384584 19255327 19773371 (more) 23406027 25157968 26619011
4	RET	Ret Proto-Oncogene	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵	20847059 20065189 20368568 (more) 18541894 21470995 23056499 21455200 9681850 19255327 22025146
5	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	25	Likely pathogenic ⁵	26619011
6	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	25	Likely pathogenic ⁵	26619011
7	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	25	Likely pathogenic ⁵	26619011
8	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	25	Likely pathogenic ⁵	26619011
9	PRKAR1A	Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha	Protein Coding	15.81	GeneCards inferred via : Publications Summaries (show sections)
10	NIBAN1	Niban Apoptosis Regulator 1	Protein Coding	6.78	GeneCards inferred via : Expressions (show sections)
11	TNS3	Tensin 3	Protein Coding	6.78	GeneCards inferred via : Expressions (show sections)
12	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.67	GeneCards inferred via : Functions (show sections)

Sources

Variations for Thyroid Tumor

ClinVar genetic disease variations for Thyroid Tumor:

⁵ (show all 42)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	KRAS	NM_033360.4(KRAS):c.182A>C (p.Gln61Pro)	SNV	Pathogenic	375966	rs121913240	GRCh37: 12:25380276-25380276 GRCh38: 12:25227342-25227342
2	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>C (p.Gly12Arg)	SNV	Pathogenic	375961	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
3	KRAS	NM_004985.5(KRAS):c.181C>A (p.Gln61Lys)	SNV	Pathogenic	177777	rs121913238	GRCh37: 12:25380277-25380277 GRCh38: 12:25227343-25227343
4	KRAS	NM_033360.4(KRAS):c.37G>A (p.Gly13Ser)	SNV	Pathogenic	375968	rs121913535	GRCh37: 12:25398282-25398282 GRCh38: 12:25245348-25245348
5	KRAS	NM_004985.5(KRAS):c.182A>T (p.Gln61Leu)	SNV	Pathogenic	45116	rs121913240	GRCh37: 12:25380276-25380276 GRCh38: 12:25227342-25227342
6	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>T (p.Gly12Val)	SNV	Pathogenic	12600	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
7	KRAS	NM_004985.5(KRAS):c.437C>T (p.Ala146Val)	SNV	Pathogenic	375962	rs1057519725	GRCh37: 12:25378561-25378561 GRCh38: 12:25225627-25225627
8	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>G (p.Gln61Arg)	SNV	Pathogenic	160364	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
9	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)	SNV	Pathogenic	35554	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
10	KRAS	NM_004985.5(KRAS):c.182A>G (p.Gln61Arg)	SNV	Pathogenic	45115	rs121913240	GRCh37: 12:25380276-25380276 GRCh38: 12:25227342-25227342
11	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)	SNV	Pathogenic	12606	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
12	KRAS	NM_004985.5(KRAS):c.35G>T (p.Gly12Val)	SNV	Pathogenic	12583	rs121913529	GRCh37: 12:25398284-25398284 GRCh38: 12:25245350-25245350
13	KRAS	NM_004985.5(KRAS):c.34G>T (p.Gly12Cys)	SNV	Pathogenic	12578	rs121913530	GRCh37: 12:25398285-25398285 GRCh38: 12:25245351-25245351
14	KRAS	NM_004985.5(KRAS):c.34G>C (p.Gly12Arg)	SNV	Pathogenic	12579	rs121913530	GRCh37: 12:25398285-25398285 GRCh38: 12:25245351-25245351
15	KRAS	NM_004985.5(KRAS):c.38G>A (p.Gly13Asp)	SNV	Pathogenic	12580	rs112445441	GRCh37: 12:25398281-25398281 GRCh38: 12:25245347-25245347
16	RET	NM_020975.6(RET):c.2753T>C (p.Met918Thr)	SNV	Pathogenic	13919	rs74799832	GRCh37: 10:43617416-43617416 GRCh38: 10:43121968-43121968
17	KRAS	NM_004985.5(KRAS):c.34G>A (p.Gly12Ser)	SNV	Pathogenic	12584	rs121913530	GRCh37: 12:25398285-25398285 GRCh38: 12:25245351-25245351
18	KRAS	NM_004985.5(KRAS):c.37G>C (p.Gly13Arg)	SNV	Pathogenic	12593	rs121913535	GRCh37: 12:25398282-25398282 GRCh38: 12:25245348-25245348
19	KRAS	NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)	SNV	Pathogenic	12582	rs121913529	GRCh37: 12:25398284-25398284 GRCh38: 12:25245350-25245350
20	RET	NM_020975.6(RET):c.1902C>G (p.Cys634Trp)	SNV	Likely Pathogenic	13918	rs77709286	GRCh37: 10:43609950-43609950 GRCh38: 10:43114502-43114502
21	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)	SNV	Likely Pathogenic	12602	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
22	KRAS	NM_004985.5(KRAS):c.38G>T (p.Gly13Val)	SNV	Likely Pathogenic	45124	rs112445441	GRCh37: 12:25398281-25398281 GRCh38: 12:25245347-25245347
23	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)	SNV	Likely Pathogenic	12613	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
24	BRAF	NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu)	SNV	Likely Pathogenic	13966	rs121913364	GRCh37: 7:140453134-140453134 GRCh38: 7:140753334-140753334
25	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)	SNV	Likely Pathogenic	12603	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
26	NRAS	NM_002524.5(NRAS):c.183A>T (p.Gln61His)	SNV	Likely Pathogenic	373003	rs121913255	GRCh37: 1:115256528-115256528 GRCh38: 1:114713907-114713907
27	BRAF	NM_004333.6(BRAF):c.1802A>C (p.Lys601Thr)	SNV	Likely Pathogenic	44818	rs397507484	GRCh37: 7:140453133-140453133 GRCh38: 7:140753333-140753333
28	HRAS, LRRC56	NM_005343.4(HRAS):c.183G>T (p.Gln61His)	SNV	Likely Pathogenic	376318	rs121913496	GRCh37: 11:533873-533873 GRCh38: 11:533873-533873
29	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>C (p.Gln61Pro)	SNV	Likely Pathogenic	376322	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
30	NRAS	NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)	SNV	Likely Pathogenic	280409	rs11554290	GRCh37: 1:115256529-115256529 GRCh38: 1:114713908-114713908
31	PIK3CA	NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val)	SNV	Likely Pathogenic	376485	rs1057519936	GRCh37: 3:178952072-178952072 GRCh38: 3:179234284-179234284
32	PIK3CA	NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr)	SNV	Likely Pathogenic	376486	rs1057519937	GRCh37: 3:178952073-178952073 GRCh38: 3:179234285-179234285
33	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)	SNV	Likely Pathogenic	376033	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
34	PIK3CA	NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp)	SNV	Likely Pathogenic	156446	rs587777790	GRCh37: 3:178917478-178917478 GRCh38: 3:179199690-179199690
35	PIK3CA	NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile)	SNV	Likely Pathogenic	179173	rs121913283	GRCh37: 3:178952074-178952074 GRCh38: 3:179234286-179234286
36	KRAS	NM_004985.5(KRAS):c.183A>T (p.Gln61His)	SNV	Likely Pathogenic	45117	rs17851045	GRCh37: 12:25380275-25380275 GRCh38: 12:25227341-25227341
37	HRAS, LRRC56	NM_005343.4(HRAS):c.181C>G (p.Gln61Glu)	SNV	Likely Pathogenic	376444	rs28933406	GRCh37: 11:533875-533875 GRCh38: 11:533875-533875
38	BRAF	NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn)	SNV	Likely Pathogenic	376286	rs121913365	GRCh37: 7:140453132-140453132 GRCh38: 7:140753332-140753332
39	PIK3CA	NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu)	SNV	Likely Pathogenic	376487	rs1057519936	GRCh37: 3:178952072-178952072 GRCh38: 3:179234284-179234284
40	NRAS	NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)	SNV	Likely Pathogenic	375874	rs11554290	GRCh37: 1:115256529-115256529 GRCh38: 1:114713908-114713908
41	AKT1	NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys)	SNV	Likely Pathogenic	13983	rs121434592	GRCh37: 14:105246551-105246551 GRCh38: 14:104780214-104780214
42	DHX32	NM_018180.3(DHX32):c.798T>G (p.Ile266Met)	SNV	Uncertain Significance	1344808		GRCh37: 10:127548223-127548223 GRCh38: 10:125859654-125859654

Sources

Expression for Thyroid Tumor

Search GEO for disease gene expression data for Thyroid Tumor.

Sources

Pathways for Thyroid Tumor

Pathways related to Thyroid Tumor according to GeneCards Suite gene sharing:

(show top 50) (show all 180)

#	Super pathways	Score	Top Affiliating Genes
1	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.84	PTEN PRKAR1A NRAS KRAS HRAS BRAF
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.84	PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
3	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.83	PTEN PRKAR1A NRAS KRAS HRAS BRAF
4	Signal Transduction ⁶⁶	13.75	AKT1 BRAF HRAS KRAS NRAS PIK3CA
5	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.58	PRKAR1A PIK3CA NRAS KRAS HRAS AKT1
6	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.56	AKT1 BRAF HRAS KRAS NRAS PRKAR1A
7	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.54	PIK3CA NRAS KRAS HRAS BRAF AKT1
8	Class I MHC mediated antigen processing and presentation ⁶⁶ Show member pathways Adaptive Immune System ⁶⁶ Antigen processing: Ubiquitination and Proteasome degradation ⁶⁶ Neddylation ⁶⁶	13.53	PTEN PIK3CA NRAS KRAS HRAS AKT1
9	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.51	PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
10	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.45	AKT1 BRAF HRAS KRAS NRAS PIK3CA
11	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.37	AKT1 HRAS KRAS NRAS PRKAR1A PTEN
12	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.35	PTEN PRKAR1A NRAS KRAS HRAS AKT1
13	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.34	PRKAR1A PIK3CA NRAS KRAS HRAS AKT1
14	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.33	PRKAR1A NRAS KRAS HRAS BRAF AKT1
15	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.33	AKT1 BRAF HRAS KRAS NRAS PIK3CA
16	ADORA2B mediated anti-inflammatory cytokines production ⁶⁶ Show member pathways Alpha-Adrenergic Signaling ⁶⁴ Androgen receptor signaling pathway ⁷⁴ Anti-inflammatory response favouring Leishmania parasite infection ⁶⁶ Beta-agonist/Beta-blocker Pathway, Pharmacodynamics ⁶⁰ CD163 mediating an anti-inflammatory response ⁶⁶ Cytoskeleton remodeling Role of PKA in cytoskeleton reorganisation ²² G alpha (z) signalling events ⁶⁶ G protein signaling pathways ⁷⁴ Glucagon signaling in metabolic regulation ⁶⁶ GPER1 signaling ⁶⁶ Hedgehog Signaling in Mammals ⁶⁴ Leishmania infection ⁶⁶ Leishmania parasite growth and survival ⁶⁶ LTC4-CYSLTR mediated IL4 production ⁶⁶ Relaxin Pathway ⁶⁴ Signal transduction cAMP signaling ²²	13.32	PRKAR1A NRAS KRAS HRAS BRAF AKT1
17	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.15	PTEN NRAS KRAS HRAS BRAF AKT1
18	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.09	PRKAR1A NRAS KRAS HRAS AKT1
19	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	13.04	PIK3CA NRAS KRAS HRAS AKT1
20	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.03	PTEN PIK3CA NRAS KRAS HRAS AKT1
21	Sertoli-Sertoli Cell Junction Dynamics ⁶⁴ Show member pathways Epithelial Tight Junctions ⁶⁴ Germ Cell-Sertoli Cell Junction Dynamics ⁶⁴	12.96	PTEN PRKAR1A NRAS KRAS HRAS BRAF
22	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.92	PIK3CA NRAS KRAS HRAS BRAF AKT1
23	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.91	PIK3CA NRAS KRAS HRAS BRAF AKT1
24	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Pathway ⁷⁰ Insulin Receptor Pathway ⁶⁴	12.91	PRKAR1A PIK3CA NRAS KRAS HRAS BRAF
25	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.9	AKT1 BRAF HRAS KRAS NRAS PIK3CA
26	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.88	PTEN PIK3CA NRAS KRAS HRAS BRAF
27	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.87	AKT1 BRAF HRAS KRAS NRAS PIK3CA
28	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.85	TNS3 PIK3CA NRAS KRAS HRAS BRAF
29	Translation Insulin regulation of translation ²² Show member pathways Butyrate-induced histone acetylation ⁷⁴ Cell adhesion PLAU signaling ²² Development CNTF receptor signaling ²² Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²² Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 ⁷⁴ Regulation of lipid metabolism Insulin signaling-generic cascades ²² Transcription Receptor-mediated HIF regulation ²² Translation Regulation of EIF2 activity ²² Translation Regulation of EIF4F activity ²² Translation inhibitors in chronically activated PDGFRA cells ⁷⁴	12.84	AKT1 HRAS PIK3CA PRKAR1A PTEN
30	MAPK-Erk Pathway ⁶⁷ Show member pathways Actin Dynamics Signaling Pathway ⁶⁷ G Protein-coupled Receptors Signaling ⁶⁷	12.84	PIK3CA NRAS KRAS HRAS BRAF
31	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.82	PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
32	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.81	AKT1 HRAS KRAS NRAS
33	DREAM Repression and Dynorphin Expression ⁶⁴ Show member pathways Arrhythmogenic right ventricular cardiomyopathy ⁷⁴ BMP Pathway ⁶⁴ Calpain Protease Regulates Cellular Mechanics ⁶⁴ Caspase Cascade ⁶⁴ nNOS Signaling in Skeletal Muscle ⁶⁴ Presynaptic depolarization and calcium channel opening ⁶⁶ TOB in Osteoblast Signaling ⁶⁴	12.8	PRKAR1A NRAS KRAS HRAS
34	CNTF Signaling ⁶⁴ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ FLT3 Signaling ⁶⁴ G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Host-pathogen interaction of human coronaviruses - MAPK signaling ⁷⁴ IL-3 Pathway ⁶⁴ Immune response Oncostatin M signaling via MAPK in human cells ²² Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells ⁷⁴ MAPK cascade ⁷⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.76	NRAS KRAS HRAS BRAF AKT1
35	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.76	NRAS KRAS HRAS BRAF AKT1
36	G-AlphaQ Signaling ⁶⁴ Show member pathways G-AlphaI Signaling ⁶⁴ PAR4-mediated thrombin signaling events ⁶¹ Thrombin Signaling ⁶⁴	12.76	AKT1 BRAF HRAS KRAS NRAS PRKAR1A
37	Insulin receptor signalling cascade ⁶⁶ Show member pathways Glucose homeostasis ⁷⁴ IGF1R signaling cascade ⁶⁶ IRS activation ⁶⁶ IRS-mediated signalling ⁶⁶ IRS-related events triggered by IGF1R ⁶⁶ PI3K Cascade ⁶⁶ SHC-related events triggered by IGF1R ⁶⁶ Signal attenuation ⁶⁶ Signaling by Insulin receptor ⁶⁶ Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) ⁶⁶ SOS-mediated signalling ⁶⁶	12.74	PIK3CA NRAS KRAS HRAS
38	G-protein signaling G-Protein alpha-i signaling cascades ²² Show member pathways Development Beta-adrenergic receptors regulation of ERK ²² G-protein signaling G-Protein alpha-s signaling cascades ²² G-protein signaling G-Protein beta/gamma signaling cascades ²² Signaling in Gap Junctions ⁶⁴	12.74	PRKAR1A NRAS KRAS HRAS BRAF AKT1
39	Malignant pleural mesothelioma ⁷⁴	12.73	PTEN PIK3CA HRAS AKT1
40	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.72	PRKAR1A NRAS KRAS HRAS BRAF AKT1
41	Signaling downstream of RAS mutants ⁶⁶ Show member pathways MAP2K and MAPK activation ⁶⁶ Negative regulation of MAPK pathway ⁶⁶ Paradoxical activation of RAF signaling by kinase inactive BRAF ⁶⁶ RAF activation ⁶⁶ Signaling by high-kinase activity BRAF mutants ⁶⁶ Signaling by moderate kinase activity BRAF mutants ⁶⁶ Signaling by RAF1 mutants ⁶⁶ Signaling by RAS mutants ⁶⁶	12.71	NRAS KRAS HRAS BRAF
42	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.71	AKT1 HRAS KRAS NRAS PIK3CA
43	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.69	PIK3CA NRAS KRAS HRAS AKT1
44	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.69	PTEN PIK3CA NRAS KRAS HRAS BRAF
45	Negative regulation of FGFR1 signaling ⁶⁶ Show member pathways FGFR1 ligand binding and activation ⁶⁶ FGFR1b ligand binding and activation ⁶⁶ FGFR1c and Klotho ligand binding and activation ⁶⁶ FGFR1c ligand binding and activation ⁶⁶ FGFRL1 modulation of FGFR1 signaling ⁶⁶ Negative regulation of FGFR2 signaling ⁶⁶ Negative regulation of FGFR3 signaling ⁶⁶ Negative regulation of FGFR4 signaling ⁶⁶ Signaling by activated point mutants of FGFR1 ⁶⁶ Signaling by FGFR1 ⁶⁶ Signaling by FGFR1 amplification mutants ⁶⁶ Signaling by FGFR3 ⁶⁶ Signaling by FGFR4 ⁶⁶ Spry regulation of FGF signaling ⁶⁶	12.68	PIK3CA NRAS KRAS HRAS BRAF
46	Signaling by NTRKs ⁶⁶ Show member pathways Activated NTRK3 signals through PI3K ⁶⁶ Activated NTRK3 signals through PLCG1 ⁶⁶ Activated NTRK3 signals through RAS ⁶⁶ Activation of TRKA receptors ⁶⁶ NGF-independant TRKA activation ⁶⁶ NTF3 activates NTRK3 signaling ⁶⁶ NTRK3 as a dependence receptor ⁶⁶ PI3K/AKT activation ⁶⁶ Retrograde neurotrophin signalling ⁶⁶ Signaling by NTRK1 (TRKA) ⁶⁶ Signaling by NTRK3 (TRKC) ⁶⁶	12.66	BRAF HRAS KRAS NRAS PIK3CA
47	Angiopoietin-like protein 8 regulatory pathway ⁷⁴ Show member pathways Insulin signaling ⁷⁴ Liver X receptor pathway ⁷⁴	12.59	PTEN PIK3CA HRAS AKT1
48	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.56	PTEN PIK3CA HRAS BRAF AKT1
49	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.54	PIK3CA NRAS KRAS HRAS AKT1
50	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.54	PIK3CA NRAS KRAS HRAS AKT1

Sources

GO Terms for Thyroid Tumor

Biological processes related to Thyroid Tumor according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.13	AKT1 BRAF HRAS KRAS RET
2	positive regulation of peptidyl-serine phosphorylation	GO:0033138	10	PIK3CA BRAF AKT1
3	Ras protein signal transduction	GO:0007265	9.99	NRAS KRAS HRAS
4	phosphorylation	GO:0016310	9.98	RET PRKAR1A PIK3CA BRAF AKT1
5	protein kinase B signaling	GO:0043491	9.88	PTEN PIK3CA AKT1
6	negative regulation of neuron apoptotic process	GO:0043524	9.86	PIK3CA KRAS HRAS BRAF
7	epidermal growth factor receptor signaling pathway	GO:0007173	9.85	AKT1 BRAF PIK3CA
8	anoikis	GO:0043276	9.8	PIK3CA AKT1
9	phosphatidylinositol 3-kinase signaling	GO:0014065	9.8	PTEN PIK3CA AKT1
10	positive regulation of protein phosphorylation	GO:0001934	9.61	NIBAN1 KRAS HRAS BRAF AKT1
11	regulation of axon regeneration	GO:0048679	9.46	PTEN BRAF
12	cellular response to decreased oxygen levels	GO:0036294	9.33	PTEN AKT1
13	MAPK cascade	GO:0000165	9.32	RET NRAS KRAS HRAS BRAF

Molecular functions related to Thyroid Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	GDP binding	GO:0019003	9.8	NRAS KRAS HRAS
2	kinase activity	GO:0016301	9.8	RET PRKAR1A PIK3CA BRAF AKT1
3	G protein activity	GO:0003925	9.43	NRAS KRAS HRAS
4	protein serine/threonine kinase activator activity	GO:0043539	9.33	PIK3CA KRAS HRAS
5	nucleotide binding	GO:0000166	9.23	RET PRKAR1A PIK3CA NRAS KRAS HRAS